Biotech Values

[DewDiligence]

GILD—The DB analyst does seem to be overly bullish, but at least is a counterpoint to your comments, which seem to be overly bearish…

I haven’t posted what I think the odds of TAF failure are, so how can anybody say that my opinion with respect to TAF is unduly bearish?

What I think needs to be highlighted (as occurred in the DB report you posted) is valuation analysis of GILD that ascribes minuscule risk—or no risk whatsoever—to TAF failure.

p.s. Yes, I meant Deutsche Bank (not Wells Fargo) in my prior post in this thread.